Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Metastatic Cutaneous Melanoma: early-phase trial registry

4 of 5 indexed Metastatic Cutaneous Melanoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 4 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Metastatic Cutaneous Melanoma: 5 US clinical trials tracked, 4 recruiting.

Metastatic Cutaneous Melanoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Fred Hutchinson Cancer Center, running 1 of these trials.

Enrollment posture brief

Registry condition metastatic-cutaneous-melanoma

OPEN 4 | RECR 80% | LATE 1 | EARLY 3 | RANK #3391 | SPON 1

Nearest open-share peer: Acute Leukemia of Ambiguous Lineage (80% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Metastatic Cutaneous Mel (th…80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Metastatic Cutaneous Melanoma

Metastatic Cutaneous Melanoma lists 4 open slots (80% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Metastatic Cutaneous Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Metastatic Cutaneous Melanoma is recruiting above its size-band peers.

    4 of 5 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Metastatic Cutaneous Melanoma research.

    Fred Hutchinson Cancer Center accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Metastatic Cutaneous Melanoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 99 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.

  4. Metastatic Cutaneous Melanoma research is mostly interventional.

    5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 22Phase 31

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2
Phase 3 1

Named interventions

Most-linked intervention names on Metastatic Cutaneous Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Ipilimumab Biological
3 trials
Computed Tomography Procedure
3 trials
Biospecimen Collection Procedure
3 trials
Nivolumab Biological
2 trials
Magnetic Resonance Imaging Procedure
2 trials
Neoantigen Peptide Vaccine Biological
1 trials
Educational Activity Other
1 trials
Encorafenib Drug
1 trials

US sites by state

Facility locations filed on Metastatic Cutaneous Melanoma trials. A trial with sites in several states counts in each.

California 2 trials
Arkansas 2 trials
Alabama 2 trials
Washington 1 trials
Ohio 1 trials
Georgia 1 trials
Arizona 1 trials
Alaska 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Metastatic Cutaneous Melanoma page

5 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Cutaneous Melanoma condition card totals 5 registered trials; most-linked intervention Ipilimumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.